Abiraterone Acetate · Regulatory label update

FDA supplemental approval: Abiraterone Acetate (Labeling)

U.S. Food and Drug Administration · June 5, 2026

Regulatory Update Why this matters to you Expert discussion

An action by a regulator. Authoritative on labelling and availability.

AI Summary

This is a regulatory action by the FDA approving a supplemental labeling change for abiraterone acetate 250 mg tablets. The record documents the approval but does not contain clinical trial data, efficacy outcomes, or comparator evidence. Clinicians should consult the updated labeling for indication, dosage, and safety information, and refer to underlying clinical trials for efficacy data.

What was studied

Regulatory label update.

Key findings

Safety

No safety, efficacy, or pharmacokinetic data are provided.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

FDA supplemental approval for abiraterone acetate labeling update; regulatory action does not establish clinical efficacy or comparative benefit.

Reported figures

Quoted from the source exactly as published.

Approval date2026-06-05

Drug strength250 mg

Caveats

This regulatory record does not report clinical trial results, efficacy data, or comparative outcomes.
The specific nature of the labeling change is not detailed in this record.
No safety, efficacy, or pharmacokinetic data are provided.
Clinical evidence underlying this approval must be sourced separately from the FDA application file or published literature.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Regulatory record; no clinical study design described.

Directness

insufficient

Labeling supplement; clinical endpoints not reported.

Consistency

insufficient

No comparative data or trial outcomes provided.

Risk of bias

insufficient

Regulatory action; study methodology not described.

Sample adequacy

insufficient

No study population or sample size reported.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Drugs@FDA record for application ANDA208371. This is a regulatory action record, not a clinical study. Brand name: ABIRATERONE ACETATE. Active ingredient: ABIRATERONE ACETATE. Sponsor: RISING. Submission type: SUPPL (supplement). Submission class: Labeling. Approval status date: 2026-06-05. Products: ABIRATERONE ACETATE, TABLET, ORAL, ABIRATERONE ACETATE 250MG.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

RisingAbiraterone Acetate